Kyntra Bio, Inc. (KYNB)
7.77
-0.25
(-3.12%)
USD |
NASDAQ |
Aug 31, 14:26
Kyntra Bio Free Cash Flow : -38.06M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.06M |
| March 31, 2026 | -21.40M |
| December 31, 2025 | -4.858M |
| September 30, 2025 | -17.14M |
| June 30, 2025 | -23.74M |
| March 31, 2025 | -76.29M |
| December 31, 2024 | -138.26M |
| September 30, 2024 | -126.23M |
| June 30, 2024 | -202.99M |
| March 31, 2024 | -274.68M |
| December 31, 2023 | -317.54M |
| September 30, 2023 | -351.81M |
| June 30, 2023 | -319.34M |
| March 31, 2023 | -241.74M |
| December 31, 2022 | -149.67M |
| September 30, 2022 | -153.18M |
| June 30, 2022 | -57.76M |
| March 31, 2022 | -52.03M |
| December 31, 2021 | -87.42M |
| September 30, 2021 | -40.68M |
| June 30, 2021 | -85.13M |
| March 31, 2021 | 92.05M |
| December 31, 2020 | 77.61M |
| September 30, 2020 | 40.43M |
| Date | Value |
|---|---|
| June 30, 2020 | 12.90M |
| March 31, 2020 | -166.41M |
| December 31, 2019 | -84.47M |
| September 30, 2019 | -58.30M |
| June 30, 2019 | -21.92M |
| March 31, 2019 | -28.38M |
| December 31, 2018 | -84.20M |
| September 30, 2018 | -68.81M |
| June 30, 2018 | -97.79M |
| March 31, 2018 | -81.74M |
| December 31, 2017 | -76.04M |
| September 30, 2017 | -88.79M |
| June 30, 2017 | -68.90M |
| March 31, 2017 | -3.958M |
| December 31, 2016 | 5.856M |
| September 30, 2016 | -15.76M |
| June 30, 2016 | -52.57M |
| March 31, 2016 | 3.798M |
| December 31, 2015 | -20.55M |
| September 30, 2015 | -6.809M |
| June 30, 2015 | -1.122M |
| March 31, 2015 | -10.49M |
| December 31, 2014 | 14.30M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vericel Corp. | 61.66M |
| Capricor Therapeutics, Inc. | -129.78M |
| ARS Pharmaceuticals, Inc. | -196.60M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -3.991M |
| Cash from Investing (Quarterly) | 17.67M |
| Cash from Financing (Quarterly) | -0.005M |
| Free Cash Flow Per Share (Quarterly) | -0.9859 |
| Free Cash Flow to Equity (Quarterly) | 15.26M |
| Free Cash Flow to Firm (Quarterly) | -1.623M |
| Free Cash Flow Yield | -121.1% |